Amicas agrees to Merge Healthcare takeover
This article was originally published in The Gray Sheet
Executive Summary
Imaging IT solutions provider Amicas agrees to be acquired by health IT firm Merge Healthcare after determining that the $248 million purchase price was a better offer than Amicas' previous $217 million deal to be bought out by private equity investment firm Thoma Bravo, Amicas announces March 5. Following the initial $5.35-per-share Thoma Bravo deal last December, Amicas announced Feb. 24 that it was considering a revised $6.05-per-share bid from Merge Healthcare (1"The Gray Sheet" March 1, 2010). Amicas will now pay an $8.6 million termination fee to Thoma Bravo (half of which will be reimbursed by Merge) and enter into a definitive merger agreement with Merge (2"The Gray Sheet" Jan. 4, 2010). The combination will "create a leading global healthcare IT provider and a pure-play medical imaging software vendor," Amicas says. Combined offerings will "range from comprehensive automation solutions for cardiology and radiology providers to enterprise content management solutions for [integrated delivery networks] to [original equipment manufacturer] solutions for health IT applications to trial, site and patient management solutions for pharmaceutical, biotechnology, medical device and contract research organizations.
You may also be interested in...
Amicas weighs Merge Healthcare takeover bid
Imaging IT solutions provider Amicas' board of directors pledges to consider an updated $248 million acquisition proposal from health IT firm Merge Healthcare as an alternative to Amicas' December agreement to be acquired for $217 million by private equity investment firm Thoma Bravo (1"The Gray Sheet" Jan. 4, 2010). While Amicas had initially dismissed Merge Healthcare's alternative offer as "highly conditional, illusory and risky," an update to the offer announced Feb. 24 included "an executed definitive commitment letter for $200 million of financing from Morgan Stanley," Amicas states. Amicas' board will now "evaluate the updated Merge proposal to determine appropriate next steps," the company said Feb. 24
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.